Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report

Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report

Multiple EGFR-mutant and ALK-mutant lung cancers are rare, and standard treatment has not been established because of the small number of cases. A 79-year-old man was found to harbor nodular shadows in right S1, right S5, and left S3. He was surgically diagnosed with stage IIB (pT3N0M0) EGFR G719X-m...

Full description

Bibliographic Details
Main Authors: Takafumi Yorozuya, Yutaro Nagano, Hirofumi Chiba, Yui Imai, Kento Yasuda, Yuta Sudo, Tetsuya Taya, Makoto Shioya
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Epidermal growth factor receptor
Anaplastic lymphoma kinase
Multiple lung cancers
Co-alternations
Repeated treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S221300712100040X

Similar Items

Similar Items